Generation and Characterization of Neutralizing Human Monoclonal Antibodies against Human Immunodeficiency Virus Type 1 Tat Antigen

Journal of Virology

Volumn 78, Issue 7, 2004, Pages 3792-3796

  Moreau, Emmanuel ^a   Hoebeke, Johan ^b   Zagury, Daniel ^c   Muller, Sylviane ^b   Desgranges, Claude ^a,d  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; EPITOPE; IMMUNOGLOBULIN ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; TOXOID; TRANSACTIVATOR PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN G;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN SECRETION; VIRUS REPLICATION; VIRUS STRAIN; WESTERN BLOTTING; ANTIBODY SPECIFICITY; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; PHYSIOLOGY; SERODIAGNOSIS; TRANSACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; TRANS-ACTIVATION (GENETICS); VIRUS REPLICATION;

EID: 1842562345     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.7.3792-3796.2004     Document Type: Article

References (35)

1. Belliard, G., A. Romieu, J. Zagury, H. Dali, O. Chaloin, R. Le Grand, E. Loret, J. P. Briand, B. Roques, C. Desgranges, and S. Muller. 2003. Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals. Vaccine 21:3186-3199.
2. Brake, D. A., J. Goudsmit, W. J. A. Krone, P. Schammel, N. Appleby, R. H. Meloen, and C. Debrouck. 1990. Characterization of murine monoclonal antibodies to the Tat protein from human immunodeficiency virus type 1. J. Virol. 64:962-965.
3. Cornille, F., K. Wecker, A. Loffet, R. Genet, and B. Roques. 1999. Efficient solid-phase synthesis of Vpr from HIV-1 using low quantities of uniformly 13C-, 15N-labeled amino acids for NMR structural studies. J. Pept. Res. 54:427-435.
4. Dayton, A. I., J. G. Sodroski, C. A. Rosen, W. C. Goh, and W. A. Haseltine. 1986. The trans-activator gene of human T cell lymphotropic virus type III is required for replication. Cell 44:941-947.
5. Demirhan, I., A. Chandra, O. Hasselmayer, and P. Chandra. 1999. Intercellular traffic of human immunodeficiency virus type 1 transactivator protein defined by monoclonal antibodies. FEBS Lett. 445:53-56.
6. Desgranges, C., J. Paire, C. Pichoud, S. Souche, D. Frommel, and C. Trepo. 1987. High affinity human monoclonal antibodies directed against hepatitis B surface antigen. J. Virol. Methods 16:281-292.
7. Felber, B. K., and G. N. Pavlakis. 1988. A quantitative bioassay for HIV-1 based on trans-activation. Science 239:184-187.
8. Frankel, A. D., and C. O. Pabo. 1988. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 55:1189-1193.
9. Gallo, R. C. 1999. Tat as one key to HIV-induced immune pathogenesis and Pat toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. USA 96:8324-8326.
10. Goldstein, G., G. Tribbick, and K. Manson. 2001. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine 19:1738-1746.
11. Gringeri, A., E. Santagostino, M. Muça-Perja, H. Le Buanec, B. Bizzini, A. Lachgar, J. F. Zagury, J. Rappaport, A. Burny, R. C. Gallo, and D. Zagury. 1999. Tat toxoïd as a component of a preventive vaccine in seronegative subjects. J. Acquir. Immune Defic. Syndr. 20:371-375.
12. Gringeri, A., E. Santagostino, M. Muca-Perja, P. M. Mannucci, J. F. Zagury, B. Bizzini, A. Lachgar, M. Carcagno, J. Rappaport, M. Criscuolo, W. Blattner, A. Burny, R. C. Gallo, and D. Zagury. 1998. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J. Hum. Virol. 1:293-298.
13. Hauber, J., A. Perkins, E. Heimer, and B. Cullen. 1987. Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events. Proc. Natl. Acad. Sci. USA 84:6364-6368.
14. Ito, M., T. Ishida, L. He, F. Tanabe, Y. Rongge, Y. Miyakada, and H. Terunuma. 1998. HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells. AIDS Res. Hum. Retrovir. 14:845-849.
15. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
16. Neimark, J., and J. P. Briand. 1993. Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. Pept. Res. 6:219-228.
17. Noonan, D. M., A. Gringeri, R. Meazza, O. Rosso, S. Mazza, M. Muça-Perja, H. Le Buanec, R. S. Accolla, A. Albini, and S. Ferrini. 2003. Identification of immunodominant epitopes in inactivated Tat vaccinated healthy and HIV-1 infected volunteers. J. Acquir. Immune Defic. Syndr. 33:47-55.
18. Opi, S., J. M. J. Peloponese, D. Esquieu, G. Campbell, J. de Mareuil, A. Walburger, M. Solomiac, C. Gregoire, E. Bouveret, D. L. Yirrell, and E. P. Loret. 2002. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J. Biol. Chem. 27:35915-35919.
19. Pilkington, G. R., L. Duan, M. Zhu, W. Keil, and R. J. Pomerantz. 1996. Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library. Mol. Immunol. 33:439-450.
20. Re, M. C., G. Furlini, M. Vignoli, E. Ramazzotti, G. Roderigo, V. De Rosa, G. Zauli, S. Lolli, S. Capitani, and M. La Placa. 1995. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J. Acquir. Immune Defic. Syndr. 10:408-416.
21. Re, M. C., M. Vignoli, G. Furlini, D. Gibellini, V. Colangeli, F. Vitone, and M. La Placa. 2001. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J. Clin. Virol. 21:81-89.
22. Rhim, H., C. O. Echetebu, C. H. Herrmann, and A. P. Rice. 1994. Wild type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase. J. Acquir. Immune Defic. Syndr. 7:1116-1121.
23. Richalet-Secordel, P., N. Rauffer-Bruyere, L. L. Christensen, B. Ofenloch-Haehnle, C. Seidel, and M. Van Regenmortel. 1997. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal. Biochem. 249:165-173.
24. Rodman, T. C., J. D. Lutton, S. Jiang, H. B. Al-Kouatly, and R. Winston. 2001. Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp. Hematol. 29:1004-1009.
25. Sblattero, D., and A. Bradbury. 1998. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 3:271-278.
26. Sblattero, D., and A. Bradbury. 2000. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat. Biotechnol. 8:75-80.
27. Secchiero, P., D. Zella, S. Capitani, R. C. Gallo, and G. Zaull. 1999. Extracellular HIV-1 Tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J. Immunol. 162:2427-2431.
28. Steinaa, L., A. M. Sorenson, J. O. Nielsen, and J. E. S. Hansen. 1994. Antibody to HIV-1 Tat proteins inhibits the replication of virus in culture. Arch. Virol. 139:263-271.
29. Tikhonov, I., T. Ruckwardt, G. Hatfield, and C. Pauza. 2003. Tat-neutralizing antibodies in vaccinated macaques. J. Virol. 77:3157-3166.
30. Tosi, G., R. Meazza, A. De Lerma Barbaro, A. D'Agostino, S. Mazza, G. Corradin, A. Albini, D. M. Noonan, S. Ferrini, and R. S. Accolla. 2000. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. Eur. J. Immunol. 30:1120-1126.
31. Valvatne, H., A. M. Szilvay, and D. E. Helland. 1996. A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular transactivation. AIDS Res. Hum. Retrovir. 12:611-619.
32. Viscidi, R. P., K. Mayor, H. M. Lederman, and A. D. Frankel. 1989. Inhibition of antigen-induced lymphcyte proliferation by Tat protein from HIV-1. Science 246:1606-1608.
33. Xiao, H., C. Neuveut, H. L. Tiffany, M. Benkirane, E. A. Rich, P. M. Murphy, and K. T. Jeang. 2000. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of co-receptor use by HIV-1. Proc. Natl. Acad. Sci. USA 97:11466-11471.
34. Zagury, D., A. Lachgar, V. Chams, L. S. Fall, J. Bernard, J. F. Zagury, B. Bizzini, A. Gringeri, E. Santagostino, J. Rappaport, M. Feldman, A. Burny, and R. C. Gallo. 1998. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc. Natl. Acad. Sci. USA 95:3851-3856.
35. Zagury, J., A. Sill, W. Blattner, A. Lachgar, H. Le Buanec, M. Richardson, J. Rappaport, H. Hendel, B. Bizzini, A. Gringeri, M. Carcagno, M. Criscuolo, A. Burny, R. C. Gallo, and D. Zagury. 1998. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1:282-292.